The prevention effect of ARB(Candesartan) upon chronic heart failure of the newly hemo-dialysis patients

UMIN ID: UMIN000000588

Registered date:30/03/2010

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Heart failure and cardiovascular disease in the newly hemo-dialysis patients
• Date of first enrollment: 2007/02/01
• Target sample size: 50
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

ARB(Candesartan) treatment with standard hypertensive therapy
standard antihypertensive therapy without any ACE-I,ARB, anti-aldosterone

Outcome(s)

• Primary Outcome: Total death, cardiovascular event, cerebrovascular event, total hospitalization
• Secondary Outcome: cardiac hemodynamics, heart function, cardiac conformation measured by each half yearly echocardiography, serum, ANP, BNP, adiponection, lipid in each half year

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: Patients with cardiovascular and/or cerebrovascular event Patients with severe liver failure and/or lung dysfunction Patients with malignancy which were diagnosed within 3 years Patients who were not suitable for this trial, judged by the attending doctor

Related Information

• Primary Sponsor: Osaka University, Graduate School of Medicine, Devision of Nephrology
• Secondary Sponsor: Osaka General Medical Center
• Source(s) of Monetary Support: Takeda Pharmaceutical Company